Anpario plc (LSE:ANP), the animal health and nutrition specialist, reported a 7% rise in first-half revenue to £24.3 million in interim results published on 9 September 2026, with adjusted EBITDA climbing 22% to £5.0 million. The board raised the interim dividend by 6%, but also cautioned that the second half had started more softly, with trading in Asia expected to remain challenged for the rest of the year.

What the company does

Anpario produces and markets natural feed additives designed to support animal health, hygiene and productivity across poultry, swine, ruminant and aquaculture markets. The group sells into a wide range of countries through a mix of its own subsidiaries and distributors, reporting its business across four broad regions: the Americas, Asia, Europe, and India, the Middle East and Africa (IMEA). Its product range includes toxin binders, acidifiers and other specialist additives intended to reduce reliance on antibiotics in livestock production.

Latest developments

The interim statement for the six months to 30 June 2026 showed a mixed regional picture. IMEA was the standout, with revenue up 56% and now accounting for around a fifth of group sales, helped by a 48% increase in India. The Americas grew 7%, with the United States up 19% offsetting an 11% decline in South America, where Brazil remained weak and Mexico was disrupted by a move to a direct sales model. Asia fell 9%, largely because toxin binder sales in the region dropped by more than 60% amid competition from lower-priced alternatives. Europe slipped 2%, although the UK grew 28%. The company also said its Bio-Vet business would be rebranded as Anpario from October.

Financial and dividend picture

Gross margin eased to 50.4% from 51.4%, while profit before tax rose 11% to £3.8 million. Diluted adjusted earnings per share increased 30% to 20.77p. The period included around £0.4 million of non-recurring professional fees relating to a corporate transaction that did not proceed. Cash stood at £11.0 million at the end of June, down from £12.4 million at the end of December 2025, reflecting £2.1 million spent on share buybacks and a working capital outflow of £3.1 million. The company said its £3 million buyback programme was completed in July 2026. The interim dividend of 3.8p per share is due to be paid on 27 November 2026 to shareholders on the register on 13 November, with an ex-dividend date of 12 November.

Sector and index context

Anpario is one of a modest number of agricultural and animal-health businesses quoted on London's junior market and is a constituent of the FTSE AIM All Share Index. Its exposure to global livestock production means results are shaped by feed costs, disease cycles and farm economics in emerging markets rather than UK consumer conditions. Its cash position sets it apart from many AIM peers that rely on external funding.

Key risks

The company flagged several pressures. Conflict in the Middle East has brought logistics disruption, raw material inflation and weaker demand in parts of Asia and Israel. Lower-cost competition in toxin binders has hit Asian sales, and management expects wider macroeconomic headwinds to persist into the second half. Distributor losses in Spain, ongoing weakness in Brazil and the transition in Mexico add execution risk. Receivable days also lengthened from 55 to 60, which bears watching for cash conversion.

What to watch next

Investors will be looking for a trading update on how the softer start to the second half has developed and whether growth in IMEA and the US can continue to offset Asian weakness. The interim dividend payment and any decision on further buybacks are further markers. Chief executive Richard Edwards said the group remains confident in the long-term prospects of Anpario (LSE:ANP).